TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20431081

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Telephone consultation
Number of subjects: 54
Study: 18711175

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 663

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 663
Study: 16422313

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (CARB, similar to the DASH diet)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Diet rich in protein (PROT, predominantly from nonmeat sources)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Diet rich in unsaturated fat (UNSAT, predominantly monounsaturated)
Number of subjects: 160
Study: 12023411

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 10486370

Group type: EXPERIMENTAL
Intervention: Biennial Haemoccult FOB tests
Number of subjects: 150251

Group type: EXPERIMENTAL
Intervention: Colonoscopy or flexible sigmoidoscopy and double contrast barium enema (DCBE)
Number of subjects: 150251

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 150251

Group type: EXPERIMENTAL
Intervention: Colonic investigation
Number of subjects: 150251

Group type: EXPERIMENTAL
Intervention: Surgery for screen detected colorectal neoplasia
Number of subjects: 150251

Group type: EXPERIMENTAL
Intervention: Surgery for screen detected benign adenomas or stage A cancers
Number of subjects: 150251

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 150251
Study: 8941691

Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg daily, starting from the 3rd postoperative day (14 patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reactive Thrombocytosis (RT) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 40
Study: 8114172

Group type: EXPERIMENTAL
Intervention: ST/ET
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: ET/ST
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 3533127

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg biphasic release formulation twice daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 34
Study: 30062458

Group type: EXPERIMENTAL
Intervention: Modified pronator quadratus repair technique involving the brachioradialis muscle insertion (test group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional radial incision through the muscle without pronator quadratus repair (standard group)
Number of subjects: 28
Study: 27513404

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac sodium 75 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac sodium 100 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no diclofenac)
Number of subjects: 150
Study: 24864182

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 g/1.73 m2 per day for 3 days)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no methylprednisolone)
Number of subjects: 83
Study: 22956705

Group type: EXPERIMENTAL
Intervention: AIM-HI intervention in enhanced offices
Number of subjects: 341
Study: 19193743

Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 18393014

Group type: EXPERIMENTAL
Intervention: Prostaglandin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syntocinon
Number of subjects: 0

Group type: COMPARATOR
Intervention: No use of prostaglandin or syntocinon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceived risk of uterine rupture
Number of subjects: 0
Study: 16316558

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ticlopidine 500 mg/d for 1 month
Number of subjects: 100
Study: 12854625

Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler with spacer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nebuliser
Number of subjects: 0
Study: 10584041

Group type: EXPERIMENTAL
Intervention: Olive oil (5 g/MJ, 19% of total energy)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sunflower oil (5 g/MJ, 19% of total energy)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Rapeseed oil (5 g/MJ, 19% of total energy)
Number of subjects: 18
Study: 8651516

Group type: EXPERIMENTAL
Intervention: Manual disinfection procedures using five disinfectants (two 2% alkaline glutaraldehyde preparations, 3.2% alkaline glutaraldehyde, 75 ppm iodophor, and 0.5% glutaraldehyde-0.03% phenolic)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Manual disinfectant procedures (one 2% glutaraldehyde, 3.2% glutaraldehyde, and 0.5% glutaraldehyde-0.03% phenolic) and automated disinfectant procedures (one 2% glutaraldehyde, 0.5% glutaraldehyde-0.03% phenolic, and 0.2% peracetic acid)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Automated disinfection procedures
Number of subjects: 5
Study: 2009789

Group type: EXPERIMENTAL
Intervention: Aerosolized BN52021 (PAF antagonist)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 21
Study: 7010650

Group type: EXPERIMENTAL
Intervention: 4% HSA in Ringer's lactate solution (RL) resuscitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ringer's lactate solution (RL) resuscitation
Number of subjects: 36
Study: 31741252

Group type: EXPERIMENTAL
Intervention: Vibrator-assisted start-stop exercises, 3 times a week for 6 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vibrator-assisted start-stop exercises + additional psychoeducation and mindfulness meditation, 3 times a week for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Additional psychobehavioral intervention
Number of subjects: 50
Study: 30770744

Group type: EXPERIMENTAL
Intervention: Free school fruit intervention (2001/2002)
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Control group (no free fruit)
Number of subjects: 1950
Study: 27914846

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide injection
Number of subjects: 147

Group type: COMPARATOR
Intervention: 20 mg triamcinolone acetonide injection
Number of subjects: 147
Study: 25246604

Group type: EXPERIMENTAL
Intervention: Extraction group (EG)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 67
Study: 24092240

Group type: EXPERIMENTAL
Intervention: CM five-element music
Number of subjects: 170

Group type: COMPARATOR
Intervention: Western music therapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: No music therapy
Number of subjects: 170
Study: 22972168

Group type: EXPERIMENTAL
Intervention: ADA alone (A group)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ADA + MTX (B group)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: ADA + MTX + other DMARDs (C group)
Number of subjects: 216

Group type: COMPARATOR
Intervention: ADA + other DMARDs (D group)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: A, B, C groups
Number of subjects: 216

Group type: COMPARATOR
Intervention: D group
Number of subjects: 216
Study: 19756348

Group type: EXPERIMENTAL
Intervention: PTH(1-84) 100 mcg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PTH(1-34) 20 mcg
Number of subjects: 10
Study: 17454663

Group type: EXPERIMENTAL
Intervention: Previously disclosed memories
Number of subjects: 181

Group type: COMPARATOR
Intervention: Previously undisclosed memories
Number of subjects: 181
Study: 15118187

Group type: EXPERIMENTAL
Intervention: Soy protein (40 g protein/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Whey protein (40 g protein/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both soy and whey groups
Number of subjects: 18
Study: 11793931

Group type: EXPERIMENTAL
Intervention: Gadobenate-dimeglumine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 27
Study: 9498442

Group type: EXPERIMENTAL
Intervention: Live attenuated chikungunya virus (CHIKV) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live attenuated VEEV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7919944

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg to 50 mg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mirtazapine and Placebo
Number of subjects: 114
Study: 2838231

Group type: EXPERIMENTAL
Intervention: Ketotifen (2 X 1 mg/day for 1 week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (13 age-matched children not suffering from asthma)
Number of subjects: 22
Study: 30411986

Group type: EXPERIMENTAL
Intervention: Phototoxic regimen of psoralen ultraviolet A (PUVA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Potent intralesional corticosteroids
Number of subjects: 40
Study: 28566363

Group type: EXPERIMENTAL
Intervention: HPV testing with cytology in triage of HPV positives (new policy)
Number of subjects: 42752

Group type: COMPARATOR
Intervention: Cervical cytology with HPV test in triage of low-grade cytological abnormalities (old policy)
Number of subjects: 42752
Study: 25376930

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch monotherapy
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Memantine plus rivastigmine transdermal patch therapy
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch or memantine add‐on therapy
Number of subjects: 146
Study: 24195218

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electric stimulation (group T)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90
Study: 21414183

Group type: EXPERIMENTAL
Intervention: Myoinositol supplementation (4 g daily) plus folic acid (400 μg daily)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Folic acid only (400 μg daily)
Number of subjects: 69
Study: 18640677

Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 30

Group type: COMPARATOR
Intervention: EGD
Number of subjects: 30
Study: 17046467

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 900

Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Number of subjects: 900

Group type: COMPARATOR
Intervention: Amodiaquine
Number of subjects: 900

Group type: COMPARATOR
Intervention: Amodiaquine plus sulphadoxine-pyrimethamine
Number of subjects: 900

Group type: COMPARATOR
Intervention: No antimalarial drugs
Number of subjects: 900
Study: 12670066

Group type: EXPERIMENTAL
Intervention: Transparent matrices and reflective wedges
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metal matrices and wooden wedges
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hybrid composite (Tetric) plus adhesive bonding agent (Syntac Classic)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Flowable composite (Tetric Flow) plus Syntac Classic
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Compomer (Dyract AP) plus adhesive bonding agent (Prime & Bond NT)
Number of subjects: 60
Study: 11074747

Group type: EXPERIMENTAL
Intervention: Once-daily enoxaparin
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Twice-daily enoxaparin
Number of subjects: 339

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 339
Study: 8753708

Group type: EXPERIMENTAL
Intervention: Intravenous administration of cephapirin sodium and gentamicin for three days
Number of subjects: 190

Group type: COMPARATOR
Intervention: Oral administration of ciprofloxacin for three days
Number of subjects: 190
Study: 1415008

Group type: EXPERIMENTAL
Intervention: Lauric acid (C12:0)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Palmitic acid (C16:0)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oleic acid (C18:1)
Number of subjects: 14
Study: 3574639

Group type: EXPERIMENTAL
Intervention: Flupentixol 2 mg/day
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Flupentixol 1 mg/day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Flupentixol 0 mg/day (control)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Flupentixol (0, 1, and 2 mg)
Number of subjects: 107
Study: 29943163

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg for 8 weeks
Number of subjects: 139

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg for 8 weeks
Number of subjects: 139
Study: 29799875

Group type: EXPERIMENTAL
Intervention: Tenofovir-containing vaginal gel or insert
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo products (vaginal gel or insert)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of semen
Number of subjects: 0
Study: 26342054

Group type: EXPERIMENTAL
Intervention: Endometrial scratch injury (ESI)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI) without ESI
Number of subjects: 154
Study: 25040168

Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 30
Study: 22745573

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine iv bolus
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1000 mg iv paracetamol infusion
Number of subjects: 90
Study: 20885427

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 22
Study: 17126520

Group type: EXPERIMENTAL
Intervention: Percutaneous treatment with expanded polytetrafluoroethylene (ePTFE)/nitinol self‐expanding stent grafts
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical femoral‐to‐above knee (AK) popliteal artery bypass with synthetic graft material
Number of subjects: 100
Study: 15979790

Group type: EXPERIMENTAL
Intervention: Painful stimulation (pressor pain) in Highs
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Painful stimulation with instruction of analgesia in Highs
Number of subjects: 18

Group type: COMPARATOR
Intervention: Painful stimulation (pressor pain) in Lows
Number of subjects: 18
Study: 12765666

Group type: EXPERIMENTAL
Intervention: Bengmark (spiral) nasojejunal tube
Number of subjects: 47

Group type: COMPARATOR
Intervention: Medicina (straight) nasojejunal tube
Number of subjects: 47
Study: 10320254

Group type: COMPARATOR
Intervention: Venoarterial pedicle preparation (group B)
Number of subjects: 112
Study: 8532276

Group type: EXPERIMENTAL
Intervention: Manual placental extraction
Number of subjects: 643

Group type: COMPARATOR
Intervention: Spontaneous placental delivery
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Glove change plus manual extraction
Number of subjects: 643

Group type: COMPARATOR
Intervention: Glove change plus spontaneous delivery
Number of subjects: 643
Study: 1858987

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 30
Study: 6343127

Group type: EXPERIMENTAL
Intervention: Parlodel
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study: 31140663

Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction to very low levels (n = 503)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction (n = 498)
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Normal nicotine content cigarettes (n = 249)
Number of subjects: 1250
Study: 30869585

Group type: EXPERIMENTAL
Intervention: Molar incisor hypomineralization (MIH)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Molar hypomineralization (MH)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Demarcated opacities presence
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Severity of MIH
Number of subjects: 342
Study: 25389213

Group type: EXPERIMENTAL
Intervention: Facebook™ advertisements (ads)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Traditional recruitment methods
Number of subjects: 220
Study: 25159623

Group type: EXPERIMENTAL
Intervention: Fast atazanavir clearance (≥9 L/h) in females
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Slow atazanavir clearance (<7 L/h) in males
Number of subjects: 786

Group type: COMPARATOR
Intervention: Middle atazanavir clearance (7 to <9 L/h)
Number of subjects: 786
Study: 23121403

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 20368491

Group type: EXPERIMENTAL
Intervention: Computer‐assisted motivational intervention (CAMI) conducted quarterly with additional visits (CAMI+ [n = 80])
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: CAMI only (n = 87)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Usual care (n = 68)
Number of subjects: 235
Study: 17428297

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 15212572

Group type: EXPERIMENTAL
Intervention: Experimental group under time constraints
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group performing at their own pace
Number of subjects: 2
Study: 12324514

Group type: EXPERIMENTAL
Intervention: AdaBoost classifier
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Boosted Decision Stump Feature Selection classifier
Number of subjects: 386
Study: 9717867

Group type: EXPERIMENTAL
Intervention: Cognitive therapy for weeks 1 to 16
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Exposure in vivo with response prevention for weeks 1 to 16
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Fluvoxamine for weeks 1 to 16 plus cognitive therapy in weeks 9 to 16
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Fluvoxamine for weeks 1 to 16 plus exposure in vivo with response prevention in weeks 9 to 16
Number of subjects: 117

Group type: COMPARATOR
Intervention: Waiting list control condition for weeks 1 to 8
Number of subjects: 117
Study: 7656956

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen at 2 L.min‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air cylinder walks (baseline)
Number of subjects: 12
Study: 2663737

Group type: EXPERIMENTAL
Intervention: Cephradine 2 g intravenously
Number of subjects: 203

Group type: COMPARATOR
Intervention: Cefuroxime 1.5 g intravenously
Number of subjects: 203
Study: 205226

Group type: EXPERIMENTAL
Intervention: digoxin/silica matrix tablets (Digacin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: digoxin/silica matrix in capsule form
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: digoxin/silica matrix dragées
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: digoxin/silica matrix formulations (in vitro)
Number of subjects: 12

Group type: COMPARATOR
Intervention: conventional tablets from digoxin-lactose trituration (in vitro)
Number of subjects: 12
Study: 30626313

Group type: EXPERIMENTAL
Intervention: Interdisciplinary patient‐centred team‐based intervention including self‐management support and a motivational approach
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 8
Study: 28654304

Group type: EXPERIMENTAL
Intervention: Active continuous diffusion of oxygen (CDO) therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham device providing moist wound therapy (MWT)
Number of subjects: 100
Study: 25453567

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX), 2% CHX gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ca(OH)2/SSL, Ca(OH)2 + SSL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ca(OH)2/CHX, Ca(OH)2 + 2% CHX gel
Number of subjects: 30
Study: 23159021

Group type: EXPERIMENTAL
Intervention: VAMA(®) cannula
Number of subjects: 90

Group type: COMPARATOR
Intervention: Berman(®) cannula
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both VAMA(®) and Berman(®) cannulas
Number of subjects: 90
Study: 21806906

Group type: EXPERIMENTAL
Intervention: Freeze dried powdered combination of Lactobacillus rhamnosus and Bifidobacterium species
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Freeze dried powdered preparation of Bacillus coagulans
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 150
Study: 19335153

Group type: EXPERIMENTAL
Intervention: One-shot technique (28F or 30F Amplatz dilator)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Alken telescopic dilators
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: One-shot technique
Number of subjects: 214
Study: 16780979

Group type: COMPARATOR
Intervention: Electron-beam irradiation at 0, 2, 4, 6, 8, and 10 kGy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Electron-beam irradiation at 8-10 kGy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Electron-beam irradiation at 6-10 kGy
Number of subjects: 4

Group type: COMPARATOR
Intervention: Electron-beam irradiation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Electron-beam irradiation at 6-8 kGy
Number of subjects: 4
Study: 14757608

Group type: EXPERIMENTAL
Intervention: WCV intervention (n = 3)
Number of subjects: 2843

Group type: EXPERIMENTAL
Intervention: Immunization intervention (n = 4)
Number of subjects: 2843

Group type: COMPARATOR
Intervention: Control (n = 4)
Number of subjects: 2843
Study: 11336156

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. over 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (H. pylori‐negative)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (H. pylori‐positive)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omeprazole treatment
Number of subjects: 12
Study: 9160036

Group type: EXPERIMENTAL
Intervention: Standard treatment (S)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Brow treatment (B)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Inner orbital treatment (IO)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Outer orbital treatment (OO)
Number of subjects: 92
Study: 7968428

Group type: COMPARATOR
Intervention: Continuous warm-up (CW)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Interval warm-up (IW)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 12
Study: 3317091

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program
Number of subjects: 17

Group type: COMPARATOR
Intervention: Support group
Number of subjects: 17